IL23A and psoriasis vulgaris: Guselkumab (Janssen Biotech, Inc., Horsham, PA, USA) is the first and only fully human IL-23 p19-subunit inhibitor approved to treat adults with moderate-to-severe plaque psoriasis and active PsA [13].